Deciphering the tumor-immune interplay in endometrial carcinoma

A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most prevalent gynecological cancers, EC continues to challenge researchers and clinicians due to its dynamic interaction with the immune microenvironment.

A Setback for TNBC Monitoring With Circulating Tumor DNA in ZEST Trial

SAN ANTONIO — A first-in-kind trial of molecular residual disease (MRD)-guided therapy in breast cancer came to an early end because of low randomization, but

December 16, 2024

Is there an association between diabetes and breast cancer risk?

The relationship between diabetes and the risk of breast cancer.

July 6, 2023

Bristol Myers Squibb’s Reblozyl reinforces market share in first-line MDS Space – Pharmaceutical Technology

In the MDS space, Reblozyl was previously approved in 2020 as a treatment for very low to intermediate-risk MDS patients with ring sideroblasts or thrombocytosis

September 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.